In a report released today, Charles Duncan from Cantor Fitzgerald downgraded Corcept Therapeutics Inc (CORT) to Hold, with a price target of $14. The company’s shares closed yesterday at $11.18, close to its 52-week low of $10.95.
According to TipRanks.com, Duncan is a 2-star analyst with an average return of 0.0% and a 46.0% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on Corcept Therapeutics Inc is a Hold with an average price target of $14.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.37 and a one-year low of $10.95. Currently, Corcept Therapeutics Inc has an average volume of 1.68M.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2018, Joseph Belanoff, the CEO of CORT sold 217,115 shares for a total of $4,125,185.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K.
